Abstracts tagged "Outcome measures"

Abstract Number: 2003 • ACR Convergence 2025
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Julia Buchfuhrer¹, Niranjan Kathe², Elizabeth Ibiloye³, Seth Kuranz⁴, Virginia Noxon-Wood⁴, Alexis Woods⁵ and Laurence Gozalo⁴, ¹JB Arthritis and Rheumatology Center, Downey, CA, ²Amgen Inc, San Diego, CA, ³Amgen Inc, Thousand Oaks, CA, ⁴Inovalon, Bowie, MD, ⁵Amgen, Detroit, MI
Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 1291 • ACR Convergence 2025
Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
Lauren Robinson¹, Lusine Ambartsumyan², Emily Willis³, Aybuke Gunalp⁴, Simone Appenzeller⁵, Ozgur Kasapcopur⁶, Sarah Ishaq⁷, Natalia Vasquez Canizares⁸ and Suzanne Li⁹, ¹Hospital for Special Surgery, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁴Cerrahpasa Medicine School, Cerrahpasa, Istanbul, Turkey, ⁵Unicamp, Campinas, São Paulo, Brazil, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Osteopathic Medicine , Touro College of Osteopathic Medicine, New York, NY, ⁸Children's Hospital at Montefiore, New York, NY, ⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

Background/Purpose: Gastrointestinal (GI) tract involvement is nearly universal in patients with systemic sclerosis (SSc) leading to significant morbidity and mortality. In a North American juvenile…
Abstract Number: 1031 • ACR Convergence 2025
Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Satani Sharkas¹, Dina Murad² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Tufts Medical Center, Boston, MA, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Rheumatoid arthritis (RA) is a growing public health concern in the United States, with increasing prevalence and disease burden over recent decades. This study…
Abstract Number: 0748 • ACR Convergence 2025
Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
Iztok HOLC¹, Metka Koren Krajnc², Marko Gačnik³ and Anja Lah⁴, ¹University Medical Center Maribor, ²⁰⁰⁰ Maribor, Slovenia, ²University Medical center, Maribor, Slovenia, ³University Medical Center Maribor, Braslovče, Slovenia, ⁴University Medical Center Maribor, Laporje, Slovenia
Background/Purpose: Giant cell arteritis (GCA) is a chronic vasculitis where relapses frequently occur. The rates of relapses of GCA have not been defined by now.We…
Abstract Number: 0376 • ACR Convergence 2025
An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users
Nicole Andersen¹, Diane Lacaille², Josee Savard³, Elham Rahme¹, Paul Fortin⁴ and Deborah Da Costa⁵, ¹McGill University, Montreal, QC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Université Laval, Quebec, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵McGill University, Pointe-Claire, QC, Canada
Background/Purpose: The use of cannabis among individuals with rheumatologic conditions has gained increasing attention due to potential effects on pain, mood, and overall quality of…
Abstract Number: 2393 • ACR Convergence 2025
Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
Samuel Wood¹, Khaled Mahmoud², Md Yuzaiful Md Yusof², Philip Conaghan², Elizabeth Hensor² and Ed Vital³, ¹University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Musculoskeletal (MSK) manifestations of SLE are the most frequently assessed domain in clinical trials. Optimal MSK assessment is contested; candidates include the binary or…
Abstract Number: 2282 • ACR Convergence 2025
Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
Nimish Mehta¹, Katie Lucero², Freddy Green³ and Karen Badal⁴, ¹Medscape, Three Bridges, NJ, ²Medscape, Newark, ³Medscape, London, United Kingdom, ⁴Medscape, New York, NY
Background/Purpose: In recent years, an increasing number of cytokines and their function in the pathophysiology of immunologic conditions have been identified, leading to the development…
Abstract Number: 1983 • ACR Convergence 2025
Documenting Transition: A Review and Intervention to Increase the Receipt of Transition Summary Letters
Kyla Blasingame¹, David McDonald¹, Karissa Chesky¹, Jimin Kim¹, charles lee¹, Tiphanie Vogel¹ and Miriah Gillispie-Taylor², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: The transition from pediatric to adult care poses unique challenges for patients with childhood-onset disease, many of whom were young at presentation and do…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 1290 • ACR Convergence 2025
Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Jin Xuan Zhou¹, Stephanie Fevrier², Paris Moaf², Lawrence Ng³, Asha Jeyanathan⁴, Louise Boulard², Deborah Levy¹, Linda Hiraki¹, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease characterized by multi-organ inflammation, alongside high frequencies of mood disorders and cognitive impairment. Adverse Childhood…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0726 • ACR Convergence 2025
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Sebastian E Sattui¹, Elizabeth Ibiloye², Niranjan Kathe³, Sam Oh⁴, Virginia Noxon-Wood⁵, Iman Mohammadi⁵, Laura Moore-Schiltz⁵ and Tingting Li⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, San Diego, CA, ⁴Amgen Inc, South San Francisco, CA, ⁵Inovalon, Bowie, MD, ⁶Washington University School of Medicine, St. Louis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
Abstract Number: 0361 • ACR Convergence 2025
Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
Mercedes Chan¹, Lori Tucker¹, Jude AlMasoud¹, Jaime Guzman², Andrea Human¹, David Cabral³, Angela How⁴, Wendy Wong⁵ and Jennifer Corpuz⁶, ¹BC Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴UBC, Vancouver, BC, Canada, ⁵University of British Columbia, Surrey, BC, Canada, ⁶UBC, New Westminster, BC, Canada
Background/Purpose: Graduating from child and family-oriented to adult-oriented health care is a vulnerable time when youth with chronic disease drop out of, or disengage from,…
Abstract Number: 2392 • ACR Convergence 2025
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Daniyal Nadeem¹, Anusheh Ali², Shravya Balmuri², Megan Mattison³, Upasana Agrawal⁴, Alexandra Zamora-Smith⁵, Karan Sachdeva⁶, Teresa leeth¹, Robert Quinet⁷, William Davis⁸, Jerald Zakem⁹, Chandana Keshavamurthy¹⁰, Xin Zhang¹¹, Sarwat Umer¹² and Samina Hayat¹³, ¹Louisiana State University Health Science, Shreveport, LA, ²Louisiana State University, Shreveport, LA, ³Louisiana State University- Shreveport, Shreveport, LA, ⁴Louisiana State University Health Sciences, Shreveport, Shreveport, LA, ⁵LSU Health Science Center in Shreveport, Shreveport, LA, ⁶Louisiana state university health shreveport, shreveport, ⁷Department of Rheumatology, Ochsner Health, New Orleans, LA, ⁸Ochsner Health System, New Orleans, LA, ⁹Ochsner Health Systems, Metairie, LA, ¹⁰banner university medical center, phoenix, AZ, ¹¹Ochsner Medical Center, New Orleans, LA, ¹²LSUHSC Shreveport, Shreveport, LA, ¹³Louisiana state university Shreveport, Shreveport, LA
Background/Purpose: Obesity, a prevalent condition, is known to exacerbate inflammation and could potentially influence the progression and severity of autoimmune diseases like Systemic lupus erythematosus…

« Previous Page
1
…
4
5
6
7
8
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].